India's foreign minister on Tuesday urged Britain to remove a rule requiring Indians visiting there to quarantine even if they are fully vaccinated.
India's Covishield vaccine, developed by AstraZeneca and manufactured in India by Pune-based Serum Institute, is not recognised by Britain under new rules despite being identical to the doses given to millions of Britons.
The rules, that come into effect next month, have caused anger, with many Indians branding the decision as discriminatory. Britons vaccinated in the United Kingdom with the same Indian-made doses are not required to quarantine.
They could also lead to a retaliation from New Delhi, with Indian government sources saying it was likely to take reciprocal steps if the issue is not quickly resolved.
"Urged early resolution of quarantine issue in mutual interest," Foreign Minister Subrahmanyam Jaishankar said in a tweet after a meeting with his British counterpart Liz Truss in New York, where both are attending the United Nations General Assembly.
The British High Commission (embassy) in New Delhi said the United Kingdom was working with India to resolve the issue.
"We are engaging with the Government of India to explore how we could expand UK recognition of vaccine certification to people vaccinated by a relevant public health body in India," a spokesperson said.
The rules, that mandate 10 days of self-isolation for travellers arriving from India, also apply to many other countries using Covishield, including most African ones.
Shashi Tharoor, an Indian opposition lawmaker and author, said on Monday he had cancelled a planned book tour of Britain in protest against the rules.
"It is offensive to ask fully vaccinated Indians to quarantine," he said.
A second lawmaker, Jairam Ramesh, said the decision "smacks of racism".
AstraZeneca is one of the key providers to Britain's vaccination program, along with U.S. peers Moderna and Pfizer.
The AstraZeneca vaccine makes up most of the doses given to Indians to date. A smaller number have taken an indigenous vaccine developed by Bharat Biotech, which is not in use in Britain.
(Reporting by Alasdair Pal and Sanjeev Miglani in New Delhi, Editing by Angus MacSwan)
